What Does the Recent Literature Say About Medicaid Expansion?: Impacts on Sexual and Reproductive Health
This brief summarizes recent studies on the impacts of Medicaid expansion on a range of sexual and reproductive health outcomes.
View the Latest: Reproductive Health
Filter
-
-
A National Survey of OBGYNs’ Experiences After Dobbs
ReportThis report, based on a nationally representative survey of office-based OBGYNs practicing in the United States, examines the provision of sexual and reproductive health care provided by OBGYNs before and after the Dobbs decision, comparing the experiences of OBGYNs practicing in states where abortion is fully banned, states with gestational restrictions, and states where abortion remains available under most circumstances.
-
One Year Since Dobbs: The Landscape of Abortion Policies Across the US
News ReleaseThere has been intense focus on abortion policies across the United States since the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization on June 24, 2022. That decision overturned Roe v. Wade, eliminating federal constitutional protections for abortion and putting the decision to restrict or protect abortion with the states.
-
A Focus on Contraception in the Wake of Dobbs
PerspectiveIn this commentary for Women’s Health Issues, a publication of the Jacobs Institute of Women’s Health, KFF experts discuss contraceptive coverage and financing policies, access points within the delivery system, and the role of mis- and disinformation.
-
What Are the Exceptions to State Abortion Bans?
News ReleaseA new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access.
-
Update on the Status of Medication Abortion and the Courts
Policy WatchThis policy watch explains the April 21, 2023 United States Supreme Court's ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA's approval of mifepristone, the medication abortion pill.
-
Q & A: Implications of Two Conflicting Federal Court Rulings on the Availability of Medication Abortion and the FDA’s Authority to Regulate Drugs
Policy WatchThis policy watch explains the two conflicting rulings on the provision of mifepristone issued by two separate District Courts on April 7, 2023, Alliance for Hippocratic Medicine v. FDA and State of Washington v. United States Food and Drug Administration.
-
Q&A: Implications of the Ruling on the ACA’s Preventive Services Requirement
Policy WatchThis post summarizes some of the key issues related to the U.S. District Court's March 30 ruling in Braidwood Management v. Becerra, which imposes new limits on the government's ability to enforce preventive service requirements nationwide.
-
Who Uses Telecontraception and Why? A Closer Look at Clients of Four Telecontraception Companies
Issue BriefBased on the findings of a nonprobability sample of 6,000 survey respondents from four telecontraception companies, this brief presents a snapshot of telecontraception users and their reasons for using these platforms.
-
Medication Abortion in the Courts: What’s at Stake?
News ReleaseAccess to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion.